Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-01-28
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of sildenafil in combination with regorafenib in patients with
progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted
for the dose escalation of the treatment combination: additional patients will be enrolled at
the MTD until a total of 12 patients have been treated at the MTD.